1. Home
  2. IMNN vs MDRR Comparison

IMNN vs MDRR Comparison

Compare IMNN & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNN
  • MDRR
  • Stock Information
  • Founded
  • IMNN 1982
  • MDRR 2015
  • Country
  • IMNN United States
  • MDRR United States
  • Employees
  • IMNN N/A
  • MDRR N/A
  • Industry
  • IMNN Biotechnology: Pharmaceutical Preparations
  • MDRR Real Estate Investment Trusts
  • Sector
  • IMNN Health Care
  • MDRR Real Estate
  • Exchange
  • IMNN Nasdaq
  • MDRR Nasdaq
  • Market Cap
  • IMNN 12.1M
  • MDRR 15.6M
  • IPO Year
  • IMNN 1985
  • MDRR 2018
  • Fundamental
  • Price
  • IMNN $0.77
  • MDRR $10.51
  • Analyst Decision
  • IMNN Buy
  • MDRR
  • Analyst Count
  • IMNN 2
  • MDRR 0
  • Target Price
  • IMNN $14.00
  • MDRR N/A
  • AVG Volume (30 Days)
  • IMNN 2.3M
  • MDRR 1.8K
  • Earning Date
  • IMNN 08-13-2025
  • MDRR 08-08-2025
  • Dividend Yield
  • IMNN N/A
  • MDRR 2.57%
  • EPS Growth
  • IMNN N/A
  • MDRR N/A
  • EPS
  • IMNN N/A
  • MDRR N/A
  • Revenue
  • IMNN N/A
  • MDRR $9,485,128.00
  • Revenue This Year
  • IMNN N/A
  • MDRR N/A
  • Revenue Next Year
  • IMNN N/A
  • MDRR N/A
  • P/E Ratio
  • IMNN N/A
  • MDRR N/A
  • Revenue Growth
  • IMNN N/A
  • MDRR N/A
  • 52 Week Low
  • IMNN $0.37
  • MDRR $9.55
  • 52 Week High
  • IMNN $3.65
  • MDRR $15.00
  • Technical
  • Relative Strength Index (RSI)
  • IMNN 40.86
  • MDRR 34.13
  • Support Level
  • IMNN $0.70
  • MDRR $9.55
  • Resistance Level
  • IMNN $0.86
  • MDRR $11.43
  • Average True Range (ATR)
  • IMNN 0.10
  • MDRR 0.39
  • MACD
  • IMNN -0.05
  • MDRR -0.10
  • Stochastic Oscillator
  • IMNN 10.34
  • MDRR 44.60

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

About MDRR Medalist Diversified REIT Inc.

Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.

Share on Social Networks: